Wednesday, October 04, 2006

Cancer drug may decrease heart function, company advises

Health Canada has recently issued advisories regarding the anticancer drug (imatinib mesylate (brand name Gleevec). Separate advisories are published for health professionals and the public.

From CBC News:
The cancer drug Gleevec may carry a risk for decreased heart function, drug maker Novartis Pharmaceuticals warned Monday.

Gleevec or imatinib mesylate is used to treat adults with a type of blood cancer called chronic myeloid leukemia and a type of cancer of the stomach and bowels known as gastrointestinal stromal tumour. ...more

No comments: